Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib + Fulvestrant in Advanced ER+/HER2- Breast Cancer
NCT03803761Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Feb 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copanlisib in breast cancer, sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicity at 30 days and Response Rate. Planned start Feb 2019; status: withdrawn.
02
Drugs
copanlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03803761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03803761.